Belgium occupies an unusual middle ground in Europe’s cannabis landscape. Personal possession of small amounts has been decriminalised for more than two decades, yet production, supply and recreational sale remain firmly prohibited. Medicinal access is limited to two licensed pharmaceutical products, and the country has no commercial framework for adult-use cannabis. For operators and investors evaluating European market entry in 2026, Belgium is a tightly controlled jurisdiction with a narrow but stable medicinal channel, an active CBD and hemp sector, and a much-discussed grey zone around cannabis social clubs.
Belgium’s legal framework: an overview
Belgian cannabis policy is governed by the 1921 Drugs Law and a series of subsequent royal decrees and joint ministerial directives. Cannabis is classified as an illegal narcotic, and trafficking, cultivation and supply all carry criminal penalties. The most significant policy shift came in 2003, when the federal government formally separated cannabis from other controlled substances and made adult possession of small quantities a low priority for prosecution. A 2005 joint directive set the operational threshold at three grams of dried cannabis, or one cultivated plant, for personal use by adults aged 18 or over.
The framework is federal, but enforcement varies across the Brussels-Capital, Flemish and Walloon regions. In practice, possession within the personal threshold typically results in a written police record rather than prosecution, while public consumption, possession near schools, and any supply activity attract significantly tougher responses.
Personal use: decriminalisation in practice
Decriminalisation in Belgium does not mean legalisation. Adults found in possession of up to three grams may face an administrative fine of between €120 and €330, but the offence is generally not pursued through the courts unless aggravating factors apply. Aggravating factors include cultivation for commercial purposes, possession in the presence of minors, or any indication of onward supply.
Cannabis social clubs have been a feature of the Belgian landscape since the early 2000s, operating on the principle that members collectively cultivate cannabis for personal consumption. Legally, the model has never been recognised. Police actions have closed several clubs over the past decade, and the legal status of collective cultivation remains contested. The clubs are widely viewed as a cultural precursor to broader reform discussions rather than a regulated commercial channel.
Medicinal cannabis in Belgium
Belgium operates one of Europe’s most restrictive medicinal cannabis frameworks. The Federal Agency for Medicines and Health Products (FAMHP) authorises only licensed cannabis-based medicinal products (CBMPs). Two are currently available: Sativex, an oromucosal spray containing equal parts THC and CBD, prescribed for spasticity in patients with multiple sclerosis; and Epidyolex, a purified cannabidiol formulation indicated for treatment-resistant epilepsy syndromes including Dravet and Lennox-Gastaut.
Magistral preparations of pure CBD may be dispensed by pharmacists on prescription, but flower-based or whole-plant medicinal cannabis is not authorised. There is no patient access scheme comparable to those in Germany, the Netherlands or the UK. Distribution is centrally controlled and prescribing is concentrated within specialist clinical pathways.
The narrowness of the framework reflects Belgium’s cautious regulatory culture and the position of successive federal health ministries. In 2022, Federal Health Minister Frank Vandenbroucke rejected calls to broaden the medicinal model, citing public health concerns. That position has not materially shifted, and the patient population accessing cannabis-based treatments in Belgium remains small relative to its neighbours.
CBD, industrial hemp and the commercial landscape
CBD products occupy a more permissive space. Since February 2020, CBD oil intended for external use has been sold through Belgian pharmacies. Cosmetic and food applications follow EU-level rules, including the Novel Food framework administered by the European Commission, which continues to constrain ingestible CBD products across the single market. CBD cannot be marketed as a medicine in Belgium without FAMHP authorisation.
Industrial hemp cultivation is permitted under a regional licensing system. Authorised varieties must contain no more than 0.3% THC, in line with the EU threshold raised under the Common Agricultural Policy in 2023, and growers must hold a permit issued by the competent regional authority. Hemp fibre, seed and CBD-extract supply chains have developed steadily, particularly in Flanders, although the sector remains modest by comparison with France, the largest hemp producer in the EU.
What this means for businesses
For investors and operators, Belgium is best understood as a controlled medicinal and industrial hemp market rather than a near-term recreational opportunity. The medicinal channel is small, with prescription volumes limited by the narrow indication base and the dominance of Sativex and Epidyolex. Companies seeking to supply Belgian patients must work through established pharmaceutical licensing pathways rather than the patient-access models familiar from Germany or the UK.
CBD and hemp businesses face a clearer commercial pathway, subject to EU Novel Food rules and Belgian product registration requirements. Distribution through pharmacy channels offers a credible route to market for compliant CBD wellness products. Industrial hemp ventures benefit from proximity to large EU processing markets and from regional support for agricultural diversification.
For policymakers and advocates, Belgium remains a country to watch. Coalition politics, the ongoing BENELUX dialogue with the Netherlands and Luxembourg, and pressure from organised-crime concerns are all live factors that may shape the next phase of reform debate.
Key considerations and next steps
Companies considering Belgium should plan around three points. First, regulatory engagement with the FAMHP is essential for any medicinal or pharmaceutical proposition. Second, EU-level rules on Novel Food authorisation and THC thresholds materially shape what is commercially viable in the CBD and hemp categories. Third, the political environment is unlikely to deliver an adult-use framework in the short term, so business cases should be built on the existing medicinal and industrial channels rather than on speculative reform.
Belgium’s framework is restrictive but stable, and it offers a narrow but predictable entry point for operators willing to work within its constraints. For a wider view of how Belgium fits within the broader European picture, the Cannabis Europa overview of European cannabis regulations in 2026 sets out the comparative landscape across the major markets. Senior leaders working through European market strategy will find further dialogue and analysis at Cannabis Europa London 2026, held at the Barbican on 26 and 27 May.